Mostrar el registro sencillo del ítem

dc.contributor.authorTarazon, E
dc.contributor.authorGil-Cayuela, C
dc.contributor.authorManzanares, MG
dc.contributor.authorRoca, M
dc.contributor.authorLago Paz, Francisca 
dc.contributor.authorGonzález Juanatey, José Ramón 
dc.contributor.authorSanchez-Lacuesta, E
dc.contributor.authorMartinez-Dolz, L
dc.contributor.authorPortoles, M
dc.contributor.authorRosello-Lleti, E
dc.date.accessioned2022-02-02T08:17:24Z
dc.date.available2022-02-02T08:17:24Z
dc.date.issued2019
dc.identifier.issn2045-2322
dc.identifier.otherhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6761203/pdf/41598_2019_Article_50413.pdfes
dc.identifier.urihttp://hdl.handle.net/20.500.11940/16075
dc.description.abstractAccumulating evidence has confirmed that the expression of sarcoplasmic reticulum calcium ATPase 2a (SERCA2a) is downregulated in heart failure and cardiac allograft rejection. Although many SERCA2a-related genes and proteins involved in the regulation of myocardial Ca(2+) fluxes have been explored, its related metabolites remain poorly studied. Our main objective was to identify circulating SERCA2a-related metabolites altered in cardiac allograft rejection and to determine whether these could serve as non-invasive biomarkers. Sixty plasma samples from adult heart transplant were included in a metabolomic analysis. Sphingosine-1 phosphate (S1P), metabolite closely related with SERCA, were increased in patients with cardiac rejection (p < 0.0001). S1P discriminated between patients with and without rejection: normal grafts vs. all rejecting grafts (AUC = 0.911, p < 0.0001), normal grafts vs. Grade 1 R (AUC = 0.819, p < 0.01), Grade 2 R (AUC = 0.911, p < 0.0001), Grade 3 R (AUC = 0.996, p < 0.0001). In addition, we found changes in key enzymes and receptors of S1P pathway analysed on explanted hearts from heart failure patients. This preliminary study reveals that circulating S1P determination could be a novel approach to detect cardiac rejection, showing a robust capability for detection that improves gradually with the severity of rejection. These alterations could be relevant to better understand the involvement of calcium regulation on the pathophysiology of rejection.en
dc.language.isoenges
dc.rightsAtribución 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subject.meshSarcoplasmic Reticulum Calcium-Transporting ATPases*
dc.subject.meshHeart Diseases*
dc.subject.meshSarcoplasmic Reticulum*
dc.subject.meshMiddle Aged*
dc.subject.meshHumans*
dc.subject.meshHeart Transplantation*
dc.subject.meshLysophospholipids*
dc.subject.meshSphingosine*
dc.subject.meshMyocardium*
dc.subject.meshHeart Failure*
dc.subject.meshGraft Rejection*
dc.titleCirculating Sphingosine-1-Phosphate as A Non-Invasive Biomarker of Heart Transplant Rejectionen
dc.typeArtigoes
dc.identifier.doi10.1038/s41598-019-50413-8
dc.identifier.pmid31554869
dc.identifier.sophos34853
dc.journal.titleScientific Reportses
dc.organizationServizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::EOXI de Santiago de Compostela - Complexo Hospitalario Universitario de Santiago de Compostela::Cardioloxíaes
dc.organizationServizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::Instituto de Investigación Sanitaria de Santiago de Compostela (IDIS)es
dc.rights.accessRightsopenAccesses
dc.subject.decsretículo sarcoplasmático*
dc.subject.decstrasplante de corazón*
dc.subject.decsATPasas transportadoras de calcio al retículo sarcoplásmico*
dc.subject.decsmediana edad*
dc.subject.decsesfingosina*
dc.subject.decslisofosfolípidos*
dc.subject.decshumanos*
dc.subject.decsenfermedades cardíacas*
dc.subject.decsrechazo del injerto*
dc.subject.decsinsuficiencia cardíaca*
dc.subject.decsmiocardio*
dc.subject.keywordCHUSes
dc.subject.keywordIDISes
dc.typefidesArtículo Originales
dc.typesophosArtículo Originales
dc.volume.number9es


Ficheros en el ítem

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución 4.0 Internacional
Excepto si se señala otra cosa, la licencia del ítem se describe como Atribución 4.0 Internacional